V 2023

Development Safety Update Report 2023 CART19

BRZOŇOVÁ, Jana

Basic information

Original name

Development Safety Update Report 2023 CART19

Name in Czech

Development Safety Update Report 2023 CART19

Authors

BRZOŇOVÁ, Jana

Edition

NA. Praha, 4 pp. NA, 2023

Publisher

ÚHKT PRAHA

Other information

Language

English

Type of outcome

Výzkumná zpráva

Field of Study

30230 Other clinical medicine subjects

Country of publisher

Czech Republic

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Organization unit

Faculty of Medicine

Keywords (in Czech)

CART19; anti-CD19; chimeric antigen receptor; Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma

Keywords in English

CART19; anti-CD19; chimeric antigen receptor; Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma

Tags

Tags

International impact
Změněno: 15/1/2024 10:21, Bc. Hana Vladíková, BBA

Abstract

V originále

Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. EudraCT 2018-004789-32, ÚHKT-CAR19-01, NCT05054257: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. (Principal Investigator: MUDr. Jan Vydra, Ph.D.,

Links

90249, large research infrastructures
Name: CZECRIN IV